Bronchodilators Market – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Bronchodilators Market By Drug Class (Phosphodiesterase Inhibitors, Anticholinergics, Sympathomimetics, Combination Drugs), By Route of Administration (Oral, Parenteral, Inhalation), By Disease Type (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Global bronchodilators Market was valued at USD 29000 Mn in 2020 and expected to grow at 5.4% Compound Annual Growth Rate (CAGR) over 2021 to 2027 to reach USD 43000 Mn by 2027 . Bronchodilators are agents dilate the bronchioles and bronchi to improve the airflow to lungs.  These are commonly used in the treatment of obstructive lung diseases such as chronic obstructive pulmonary disease (COPD) emphysema, asthma, and other lung diseases. Bronchodilators are majorly classified based on their duration of action such as short-acting and long-acting. Majorly used bronchodilators are include sympathomimetics, phosphodiesterase inhibitors, and anticholinergics among others. Bronchodilators are medications that relax the muscles that constrict the airways. Bronchodilators widen the airway, allowing more air to flow in and out. Bronchodilators are also used to help the lungs clear mucus. These medications are administered to patients with respiratory problems using nebulizers or inhalers. In addition, bronchodilators used inhalation have an influence on mucociliary clearance. Bronchodilators relax the muscles of the lungs and enlarge the airways, which helps to cure obstructive lung disease (bronchi). Asthma and chronic obstructive pulmonary disease (COPD) are treated with them (COPD). The rise in the prevalence of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) around the world is fueling the expansion of the bronchodilators market. Furthermore, the market is expected to develop due to an increase in disposable income, a growing elderly population, and increased public awareness of healthcare. Furthermore, rising use of bronchodilators for cystic fibrosis treatment propels the market forward. However, the market is expected to be hampered by bronchodilator side effects and regulatory regulations about the safety and efficacy of bronchodilators.

Bronchodilators Market

MARKET SUMMARY
-
5.4% CAGR
  • Study Period– 2021-2027
  • Base Year– 2020
  • CAGR– 5.4%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Bronchodilators Market

  • The report on global Bronchodilators Market gives historical, current, and future market sizes (US$ Bn) on the basis of drug class, route of administration, disease type, distribution channel and geography.
  • Bronchodilators Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Hoffmann La Roche Ltd. (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Novartis AG (Switzerland)
  • Merck & Co. Inc. (U.S.)
  • AstraZeneca plc (U.K.)
Dynamics

Bronchodilators Market

Increase in the aging population coupled with rise in prevalence of various lung diseases such as asthma and COPD surge the global bronchodilators market. Moreover, rise in R&D expenditure for the development newer drugs, increase in geriatric population, environmental factors such as air pollution, rise in incidence of respiratory disorders in children, government initiation to improve awareness about the lung diseases, technological advancements of the inhalation devices, and rise in disposable income are propel the global market over the forecast years. However, stringent regulations for the product approval, high cost of products, adverse effects associated with the long term usage of drugs, and rise in awareness programs to prevent the respiratory disorders are restrain the growth of global bronchodilators market.


North-America got significant share

Bronchodilators Market

Geographically, global bronchodilators market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America market is growing due to rise in R&D for the innovation of newer drugs, rise in prevalence of COPD and asthma, rise in demand for the combination therapies are anticipated to fuel the market. Europe market driven by increase in adoption of newer bronchodilators, rise in disposable income, and rise in awareness about the bronchodilators are spur the market. However, Asia Pacific market has a lucrative growth, attributed to large patient pool in India and China, grow in healthcare expenditure, and launch of newer drugs in Asia Pacific region are bolster the market over the forecast years.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, country market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Bronchodilators Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Hoffmann La Roche Ltd. (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Novartis AG (Switzerland)
  • Merck & Co. Inc. (U.S.)
  • AstraZeneca plc (U.K.)
  • GlaxoSmithKline (U.S.)
  • Aquinox Pharmaceuticals (Canada)
  • MediciNova, Inc. (U.S.)
  • Gilead Sciences, Inc. (U.S.)
  • Biomarck Pharmaceuticals (U.S.)

Description

Global bronchodilators Market was valued at USD 29000 Mn in 2020 and expected to grow at 5.4% Compound Annual Growth Rate (CAGR) over 2021 to 2027 to reach USD 43000 Mn by 2027 . Bronchodilators are agents dilate the bronchioles and bronchi to improve the airflow to lungs.  These are commonly used in the treatment of obstructive lung diseases such as chronic obstructive pulmonary disease (COPD) emphysema, asthma, and other lung diseases. Bronchodilators are majorly classified based on their duration of action such as short-acting and long-acting. Majorly used bronchodilators are include sympathomimetics, phosphodiesterase inhibitors, and anticholinergics among others. Bronchodilators are medications that relax the muscles that constrict the airways. Bronchodilators widen the airway, allowing more air to flow in and out. Bronchodilators are also used to help the lungs clear mucus. These medications are administered to patients with respiratory problems using nebulizers or inhalers. In addition, bronchodilators used inhalation have an influence on mucociliary clearance. Bronchodilators relax the muscles of the lungs and enlarge the airways, which helps to cure obstructive lung disease (bronchi). Asthma and chronic obstructive pulmonary disease (COPD) are treated with them (COPD). The rise in the prevalence of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) around the world is fueling the expansion of the bronchodilators market. Furthermore, the market is expected to develop due to an increase in disposable income, a growing elderly population, and increased public awareness of healthcare. Furthermore, rising use of bronchodilators for cystic fibrosis treatment propels the market forward. However, the market is expected to be hampered by bronchodilator side effects and regulatory regulations about the safety and efficacy of bronchodilators.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX